PHK
MLTX icon

Point72 Hong Kong’s MoonLake Immunotherapeutics MLTX Stock Holding History

Point72 Hong Kong’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-188
Closed -$2K – 2063
2020
Q4 		$2K Buy
+188
New +$2K ﹤0.01% 1648

Other funds holding MLTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Hong Kong's MLTX Position: Q1 2021 in Review

Point72 Hong Kong sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2021, closing a stake of 188 shares — an estimated $2K sold.

Point72 Hong Kong first reported a position in MLTX in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 42 funds tracked by Wall St. Rank hold MLTX as of Q1 2021.

  • Point72 Hong Kong reported no remaining MoonLake Immunotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 188 MoonLake Immunotherapeutics shares in Q1 2021, an estimated $2K.
  • Point72 Hong Kong first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 1 quarter.
  • Point72 Hong Kong's MoonLake Immunotherapeutics position peaked at $2K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2021.

Based on Point72 Hong Kong's 13F filing for Q1 2021, filed 17 May 2021.